We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Shares of Acorda Therapeutics Inc. more than tripled Monday, hitting a new 52-week high, after the biotech drug developer announced the success of a late-stage clinical trial to test its treatment to improve the walking ability of multiple sclerosis patients.
Actavis U.S., the United States manufacturing and marketing division of the international generic pharmaceutical company Actavis Group, announced that it has received approval from the U.S. Food & Drug Administration to market Trimipramine Maleate Capsules.
AnorMED Inc. said Monday it will receive a $3 million milestone payment from Shire Pharmaceuticals Group PLC, based on Shire's recent licensing approval in Britain to sell Fosrenol as a treatment for high phosphate levels in the blood, which occurs in patients undergoing dialysis as a result of chronic kidney failure.
UCB and sanofi-aventis announced that they have entered into an agreement to co-promote in the United States the prescription antihistamine medicine, Xyzal (levocetirizine dihydrochloride).
A nine-year-old federal program meant to stimulate pediatric clinical trials has been only partially successful, according to an article in the Sept. 13 edition of the Journal of the American Medical Association (JAMA).
Despite warnings from the federal government and the pharma industry about the potential for drugs purchased from foreign pharmacies to be counterfeit, four out of five Americans favor legalizing importation of drugs if they are cheaper, according to a recent poll.
The FDA should be given the authority to impose severe punishments on drug manufacturers who don't live up to their postmarketing commitments, according to an Institute of Medicine (IOM) report that offered a harsh assessment of the agency's current drug safety efforts.
POZEN Inc., announced the receipt of the $40 million initial upfront payment from AstraZeneca in connection with the exclusive global collaboration agreement between the two companies.